Introduction
Estrogens are important in the growth of breast cancers in both pre-and post-menopausal women and, estrogen sensitivity in breast cancer increases with patient age. Two-thirds of breast cancer tumors in post-menopausal women are positive for estrogen and/or progesterone receptors, compared to pre-menopausal women where the presence of these receptors appears in less than half of tumors. The endogenous ligands for these receptors, estrogens and progestins, stimulate cell proliferation directly by increasing the rate of early response genes and indirectly through the stimulation of growth factors. 1 Such dependence on sex steroids for tumor growth makes hormonal therapy an inviting strategy for treatment. 2 Two general strategies have developed for the treatment of hormone-dependent breast cancer. The first strategy is to block estrogen receptor action by disrupting its interaction with and activation by estradiol. Antiestrogens, such as tamoxifen, bind to the estrogen receptor and interfere with the transcription of estrogen-induced genes. The efficacy of tamoxifen has been established in the treatment of post-menopausal, hormone-responsive breast cancer. 3 Tamoxifen increases long-term survival, reduces recurrences, and has few side effects. In addition to tamoxifenÕs antagonistic effects in breast tissue, it also behaves as a weak or partial agonist in other tissues. While exhibiting antagonistic activity in the breast, the partial agonist effects in other parts of the body have lead to the formation of secondary tumors of the liver and uterus. 4 A second pharmacological approach is to block estradiol synthesis catalyzed by the cytochrome P450 enzyme aromatase (CYP19). Aromatase has been a particularly attractive target for inhibition in the treatment of hormone-dependent breast cancer since the aromatization of androgen substrates is the terminal and rate-limiting step in estrogen biosynthesis. [5] [6] [7] [8] In addition to the large number of aromatase inhibitors that have arisen from medicinal chemistry efforts in pharmaceutical and academic laboratories, 5-9 a significant number of natural product aromatase inhibitors have been identified. [10] [11] [12] The flavonoids are one of the largest classes of naturally occurring aromatase inhibitors. 10 Generally, flavones and flavanones have higher aromatase inhibitory activity than isoflavones. Chrysin and Biochanin A (BCA) are two of the most potent examples of flavone and isoflavone identified to date, respectively (Fig. 1) . The flavone, chrysin, is 20-fold more potent than BCA in terms of IC 50 values. 11, 12 This large difference in potency is the likely reason why there has been little effort to develop aromatase inhibitors on an isoflavone scaffold. heme iron. Taken together with the density functional theory (DFT) calculations, these observations explain the superior potency of the imidazole analog relies on the availability of the nitrogen lone pair electrons to coordinate with the aromatase P450 heme.
In general, imidazole isoflavone inhibitors presented in this work share similar structure activity relationships to those reported for 2-(4-pyridylmethyl)thioisoflavones.
14 Regardless of the 7-substituent, a decrease in potency was observed when a methoxy group was introduced at the 4 0 -position. Additionally, the relative decrease in potency is dependent on the nature of the 7-substituent. 4 0 ,7-Dimethoxy analog, 2b, is 2.6-fold less potent than the 7-methoxy analog 2a. The loss of potency is more pronounced when considering the 7-benzyloxy analogs. The presence of the 4 0 -methoxy in 2d results in a nine-fold loss of activity when compared to 2c. 4 0 ,7-Dimethoxy-(4-pyridylmethylthio)isoflavone and 7-benzyloxy-4 0 -methoxy-2-(4-pyridyl-methylthio)isoflavone are 1.2-and 2.5-times less active than their 4 0 -H analogs. This observation may indicate the nature of the 4 0 -substituent may be a more important factor in the imidazole isoflavones in terms of aromatase inhibition.
In enzyme kinetic studies, imidazole isoflavones 2a d demonstrated typical competitive-type inhibition in the Lineweaver Burk plots ( Fig. 2 for 2c ; plots for 2a, b, d not shown) supporting their inhibition of aromatase by competing with the natural substrate for the active site. K i /K m ratios of imidazole isoflavones were calculated as relative inhibitory potency and the same activity trend is observed as in the dose response studies. Compound 2c demonstrates 48-fold enhancement in potency compared to the natural product lead, BCA. As reflected by its relative potency, imidazole analog 2c is 4.4-fold more potent than the widely characterized inhibitor AG, which is in agreement within the expected experimental uncertainty of the result determined in the dose response studies (5.4-fold enhancement in potency compared to AG). The results of the present enzyme kinetic studies emphasize the importance of these structural modifications for optimization of aromatase inhibition by isoflavones.
Conclusion
Our recent work on 2-(4-pyridylmethylthio)isoflavones demonstrated for the first time that effective isoflavone-based aromatase inhibitors can be constructed by the introduction of appropriate nitrogen-containing heterocycle. This study further extends this concept that aromatase inhibitory activity can be achieved with the isoflavone nucleus by introduction of an appropriate heme-coordinating nitrogen heterocycle at the 2-position of the isoflavone. Comparable potency to the 2-(4-pyridylmethylthio)isoflavones can be obtained by introducing an imidazole moiety at the 2-position. Enzyme kinetic analyses of imidazole isoflavones reveal these compounds interact competitively with the aromatase active site. As revealed by DFT calculations and the difference spectra of ligand binding, the superiority of this heterocycle to achieve aromatase inhibition may lie in the electronic structure of the nitrogen heterocycle itself. While investigations are currently underway to resolve further aspects of the enzyme ligand interactions, these compounds are additional leads in our repertoire of potent aromatase inhibitors.
Experimental section Chemistry
Chemicals were commercially available and used as received without further purification, unless otherwise noted. Moisture sensitive reactions were carried out under a dry argon atmosphere in flame-dried glassware. Solvents were distilled before use under argon. Tetrahydrofuran was distilled from sodium metal in the presence of benzophenone; dichloromethane was distilled from calcium hydride. Thin layer chromatography was performed on pre-coated silica gel F254 plates (Whatman). Silica gel column chromatography was performed using silica gel 60A (Merck, 230-400 Mesh). Melting points were determined in open glass capillaries using a Thomas Hoover apparatus and are uncorrected. Infrared spectra were recorded on a Nicolet Protégé 460 spectrometer using KBr pellets. High-resolution electrospray ionization mass spectra were obtained on the Micromass QTOF Electrospray mass spectrometer at The Ohio State Chemical Instrumentation Center. All the NMR spectra were recorded on a Bruker DPX 250, or Bruker DRX 400 model spectrometer in either DMSO-d 6 or CDCl 3 . Chemical shifts (d) for 1 H NMR spectra are reported in parts per million to residual solvent protons. Chemical shifts (d) for 13 C NMR spectra are reported in parts per million relative to residual solvent carbons.
General method A for the preparation of 2-(alkylsulfonyl)isoflavones (1a-d)
A mixture of 7-alkoxy-3-aryl-2-(methylthio)-4H-1-benzopyran-4-one (8.0 mmol) and 3-chloroperoxybenzoic acid (mCPBA) (4.14 g, 24 mmol) in CH 2 Cl 2 (80 mL) were stirred under reflux for 2 h. After the solvent was removed under reduced pressure, the residue was suspended in diethyl ether and hexane (1:1, 100 mL), sonicated, and placed in a refrigerator overnight. The insoluble solid was collected by filtration, washed with diethyl ether and hexane (1:1) several times, and recrystallized from ethyl acetate to give desired product.
7-Methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-4-one (1a). Compound 1a was synthesized from 7-methoxy-2-(methylthio)-3-phenyl-4H-1-benzopyran-4-one (2.39 g, 8.0 mmol) using General Method A, and 2.59 g (98%) of the title compound was obtained as a pale yellow solid: mp 208 210°C; HRMS calculated for C 17 (2a-d and 3a-d) A solution of 7-alkoxy-3-aryl-2-(methylsulfonyl)-4H-1-benzopyran-4-one (1.0 mmol) in DMF (1 mL) was added to a stirred solution of a nucleophile (as a sodium salt purchased or generated in situ by the treatment of sodium hydride) in DMF (3 mL) at 0°C. After stirring at 0°C for 0.5 h, most reactions were completed according to TLC. The reaction mixture was allowed to warm to room temperature over 1 h, then cooled to 0°C, and quenched with saturated aqueous NH 4 Cl solution. After the volatile solvents were removed in vacuo, the residual solid was suspended in a mixture of water and EtOAc, ultrasonicated for 5 min, and cooled to 0°C. Insoluble solid was collected by filtration and the filter cake was washed with EtOAc/hexane mixture to give desire product. The filtrate was extracted with EtOAc twice (2 · 10 mL), and the combined organic layer was washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The remnant was purified by silica gel column chromatography (eluting with MeOH/CHCl 3 ) to collect additional product. The combined solid was further purified by recrystallization.
2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzopyran-4-one (2a).
Compound 2a was synthesized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-4-one (0.330 g, 1.0 mmol) and sodium salt of imidazole (0.180 g, 2.0 mmol, purchased) using General Method B, and 0.231 g (73%) of the title compound was obtained as a white solid (recrystallized from EtOAc): mp 217 219°C; HRMS calculated for C 19 
2-(1H-Imidazol-1-yl)-7-methoxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one (2b).
Compound 2b was synthesized from 7-methoxy-3-(4-methoxyphenyl)-2-(methylsulfonyl)-4H-1-benzopyran-4-one (0.36 g, 1.0 mmol) and sodium salt of imidazole (0.180 g, 2.0 mmol, purchased) using General Method B, and 0.324 g (93%) of the title compound was obtained as a white solid (recrystallized from EtOH): mp 232 233°C; HRMS calculated for C 20 7-Methoxy-3-phenyl-2-(1H-1,2,4-triazol-1-yl)-4H-1-benzopyran-4-one (3a). Compound 3a was synthesized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-4-one (0.165 g, 0.5 mmol) and sodium salt of 1,2,4-triazole (0.091 g, 1.0 mmol, purchased) using General Method B, and 0.144 g (90%) of the title compound was obtained as a white solid (recrystallized from EtOAc): mp 188.5 189.5°C; HRMS calculated for C 18 H 13 N 3 NaO 3 (M+Na) + 342.0855, found 342.0843. IR (KBr) 1643, 1619, 1575, 1502, 1429, 1337, 1262,  1217, 1203, 1124, 1104, 1060, 993, 920, 837, 831, 785 7-Methoxy-2-(1-methyl-1H-imidazolyl-2-thio)-3-phenyl-4H-1-benzopyran-4-one (3c). Compound 3c was synthesized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-4-one (0.165 g, 0.5 mmol), 2-mercapto-1-methylimidazole (0.171 g, 1.5 mmol), and sodium hydride (0.036 g, 1.5 mmol) using General Method B, and 0.175 g (96%) of the title compound was obtained as a white solid (recrystallized from 7-Methoxy-3-phenyl-2-(1H-1,2,4-triazolyl-3-thio)-4H-1-benzopyran-4-one (3d). Compound 3d was synthesized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-4-one (0.165 g, 0.5 mmol), 1H-1,2,4-triazole-3-thiol (0.152 g, 1.5 mmol), and sodium hydride (0.036 g, 1.5 mmol) using General Method B, and 0.075 g (43%) of the title compound was obtained as a pale yellow solid (recrystallized from EtOH): mp 246 247°C; HRMS calculated for C 18 
Enzymology
Preparation of human placental microsomes. Human term placentas were processed immediately after delivery from The Ohio State University Hospitals at 4°C. The placenta was washed with normal saline and connective and vascular tissue was removed. Microsomes were prepared from the remaining tissue using the method described by Kellis and Vickery. 20 Microsomal suspensions were stored at À80°C until required.
Inhibition study. Inhibition of human placental aromatase was determined by monitoring the amount of 3 H 2 O released as the enzyme converts [1b-3 H]androst-4-ene-3,17-dione to estrone. Ten inhibitor concentrations ranging from 100 nM to 50 lM were evaluated. Aromatase activity assays were carried in 0.1 M potassium phosphate buffer (pH 7.0) with 5% propylene glycol. All samples contained a NADPH regenerating system consisting of 2.85 mM glucose-6-phosphate, 1.8 mM NADP + and 1.5 units of glucose-6-phosphate dehydrogenase (Sigma, St. Louis, MO). Samples contained 100 nM androst-4-ene-3,17-dione (400,000 450,000 dpm). Reactions were initiated with the addition of 50 lg microsomal protein. The total incubation volume was 2.0 mL. Incubations were allowed to proceed for 15 min in a shaking water bath at 37°C. Reactions were quenched by the addition of 2.0 mL of chloroform. Samples were then vortexed and centrifuged for 5 min and the aqueous layer was removed. The aqueous layer was subsequently extracted twice in the same manner with 2.0 mL chloroform. A 0.5 mL aliquot of the final aqueous layer was combined with 5 mL 3a70B scintillation cocktail (Research Products International Corp., Mt. Prospect, IL) and the amount of radioactivity determined. Each sample was run in triplicate and background values were determined with microsomal protein inactivated by boiling. Samples containing 50 lM (±) aminoglutethimide (Sigma, St.
Louis, MO) were used a positive control. IC 50 dose response data were analyzed with the Graphpad Prism (Version 3.0) program. Kinetic study. Enzyme kinetic studies of compounds 2a d were conducted to investigate the nature of aromatase inhibition. Michaelis-Menten enzyme kinetic parameters were determined by varying the concentration of androst-4-ene-3,17-dione from 50 to 500 nM in the presence of a fixed concentrations of 0, 100, 500, 2000 nM (2a,c) and 0, 2000, 5000, 10,000 nM (2b,d). Assay conditions were the same as those described in the IC 50 studies except reactions were initiated by the addition of 15 lg microsomal protein. Analysis of the enzyme kinetic data was performed with the weighted linear regression analysis previously described by Cleland.
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Determination of P450 difference spectra. Immunoaffinity-purified human placental cytochrome P450 aromatase (Hauptman-Woodward Medical Research Institute, Buffalo, NY) was diluted to 7.0 lg/mL with 0.1 M Tris Buffer (pH 7.4) in a 50 lL quartz UV cell, and the absorbance was scanned from 350 to 500 nm. 0.1 M Tris Buffer (pH 7.4) was used as a reference. Compounds 2a and 3a were introduced into the sample cell in 1 lL of ethanol for a final concentration of 50 lM, and the spectrum was rescanned at the aforementioned wavelength range. Multiple scans were taken to ensure spectrum stability for aromatase and aromatase/inhibitor mixtures. Absorbance values of aromatase were subtracted from the aromatase/inhibitor values to generate the difference spectrum.
